ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) growth accelerates
Q1 FY2026 weighted avg shares (diluted) of 45.07M shares rose 32.9% year over year, ahead of the +19.2% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 17.2% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Weighted avg shares (diluted) increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +32.9% holds above the trailing-twelve-month pace of +19.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 38.46M USD
- Year-over-year change
- +22.2%
- 4-year CAGR
- +134.3%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.46M | +22.2% |
| FY2024 | 2024-12-31 | 31.47M | -1.5% |
| FY2023 | 2023-12-31 | 31.96M | -4.6% |
| FY2022 | 2022-12-31 | 33.49M | +2524.4% |
| FY2021 | 2021-12-31 | 1.28M | — |
Weighted Avg Shares (Diluted) vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 weighted avg shares (diluted) of 40.11M shares is the lowest of the 11 companies compared; the peer median is 101.7M shares.
- Its year-over-year change of +19.2% is the 3rd highest of 11, against a peer median of +4.0%.
- Over three fiscal years its annual growth of +4.7% compares with a peer median of +16.5%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 353.26M | +9.5% | +16.4% | |
| LTM Sep 2026 | 310.86M | +9.7% | +32.5% | |
| LTM Jul 2026 | 271.85M | -6.1% | -4.6% | |
| LTM Jun 2025 | 174.57M | +1.2% | +1.0% | |
| LTM Jun 2026 | 110.81M | +34.8% | +125.3% | |
| LTM Mar 2026 | 92.59M | +31.1% | +30.3% | |
| LTM Mar 2026 | 88.86M | +4.6% | +28.8% | |
| LTM Mar 2026 | 60.14M | +2.0% | +12.5% | |
| LTM Mar 2026 | 57.01M | +0.9% | +16.7% | |
| LTM Mar 2026 | 50.86M | +3.4% | +4.1% | |
| LTM Mar 2026 | 40.11M | +19.2% | +4.7% | |
| Peer median (excluding AVBP) | 101.7M | +4.0% | +16.5% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 6.43M | 30.43M | 64.88M | 79M | 153.35M |
| Selling, General & Admin | 2.26M | 6.47M | 9.71M | 15.3M | 24.18M |
| Operating Expenses | 8.7M | 36.91M | 74.59M | 94.31M | 177.53M |
| Depreciation & Amortization | 0 | 36.91M | 0 | 0 | 0 |
| EBITDA | (51.61M) | 0 | (69.33M) | (80.49M) | (166.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (8.7M) | (36.91M) | (74.59M) | (94.31M) | (177.53M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 5.26M | 13.82M | 11.23M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42.91M) | 0 | 5.26M | 13.82M | 11.23M |
| Income Before Tax | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| EPS (Diluted) | (40.44) | (1.10) | (2.17) | (2.56) | (4.32) |
| Weighted Avg Shares | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
| Weighted Avg Shares (Diluted) | 1.28M | 33.49M | 31.96M | 31.47M | 38.46M |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.